Most people taking Wegovy lose about 15% of their body weight over roughly 16 months. In the largest clinical trial, participants without type 2 diabetes lost an average of 14.9% of their starting weight at 68 weeks, compared to just 2.4% in the placebo group. For someone who weighs 250 pounds, that translates to roughly 37 pounds lost.
That’s the average, though. Individual results vary significantly, and several factors influence where you’ll land on the spectrum.
What the Clinical Trials Found
Wegovy’s headline number comes from the STEP 1 trial, which enrolled nearly 2,000 adults with obesity or overweight who did not have type 2 diabetes. Over 68 weeks of once-weekly injections alongside lifestyle changes (diet and exercise counseling), participants lost a mean of 14.9% of their body weight. The placebo group, receiving the same lifestyle counseling without the drug, lost 2.4%.
For people with type 2 diabetes, the results are meaningful but more modest. In the STEP 2 trial, participants with type 2 diabetes lost an average of 9.6% of their body weight at 68 weeks, compared to 3.4% with placebo. About 69% of those on Wegovy lost at least 5% of their weight, versus 29% on placebo. The smaller effect in people with diabetes is a consistent pattern seen across weight loss medications, likely related to how insulin resistance and diabetes medications affect metabolism.
Not Everyone Responds the Same Way
The 15% average masks a wide range of individual outcomes. In clinical trials at the full 2.4 mg dose, roughly 50% to 55% of participants lost more than 15% of their body weight, putting them well above the average. On the other end, 10% to 30% of participants were classified as non-responders, losing less than 5% of their body weight.
In one retrospective analysis, about 18% of patients had a non-response (under 5% weight loss), 48% had a moderate response (5% to 15%), and 34% had a hyper-response (over 15%). So roughly one in three people loses substantially more than the average, while close to one in five sees minimal results. If you’ve been on Wegovy for several months at the full dose and haven’t lost at least 5% of your starting weight, you may fall into that non-responder category.
How the Dose Ramps Up
Wegovy doesn’t start at full strength. The dose increases gradually over 16 weeks to reduce side effects, particularly nausea. The schedule starts at 0.25 mg weekly for the first four weeks, then steps up to 0.5 mg, 1 mg, and 1.7 mg in four-week intervals before reaching the maintenance dose of 2.4 mg at week 17. Most of the weight loss in clinical trials occurred during the months at the full maintenance dose, so early results during the ramp-up period aren’t a reliable predictor of your final outcome.
If 2.4 mg causes side effects you can’t tolerate, the maintenance dose can be reduced to 1.7 mg. A higher-dose formulation of 7.2 mg has also been approved, which has shown weight loss of around 21% in studies.
How Wegovy Causes Weight Loss
Wegovy works by mimicking a gut hormone called GLP-1 that your body naturally releases after eating. The drug activates receptors involved in appetite, satiety, and energy regulation. In practical terms, it makes you feel full sooner, reduces hunger between meals, and slows how quickly food leaves your stomach. It also interacts with leptin, another hormone that helps regulate appetite. The combined effect is that most people simply eat less without feeling like they’re fighting constant cravings.
What Happens If You Stop
Weight regain after stopping Wegovy is significant and well-documented. In the STEP 4 trial, participants first took Wegovy for 20 weeks, then were randomly assigned to either continue or switch to placebo. Over the next 48 weeks, those who continued lost an additional 7.9% of their body weight. Those who switched to placebo regained an average of 6.9% of their body weight during that same period.
This means the drug’s effects depend on continued use. Stopping Wegovy doesn’t reset your biology; the appetite suppression goes away, and the weight tends to come back. This is consistent with how obesity is treated as a chronic condition requiring ongoing management rather than a short-term fix.
How Wegovy Compares to Zepbound
Zepbound (tirzepatide) is the most direct competitor, and it produces greater weight loss in head-to-head testing. In a comparative study, participants on Zepbound at the 10 mg or 15 mg dose lost an average of 20.2% of their body weight at 72 weeks, while those on Wegovy at the 1.7 mg or 2.4 mg dose lost 13.7%. The newer 7.2 mg formulation of Wegovy narrows that gap considerably, with results around 21%.
Side Effects and Staying on Treatment
Gastrointestinal symptoms are the most common side effects: nausea, diarrhea, vomiting, and constipation. These tend to be worst during the dose escalation period and improve over time for most people. Despite the frequency of these complaints, only about 4.3% of participants in clinical trials permanently stopped Wegovy because of GI side effects. The gradual dose increase is specifically designed to minimize these problems, which is why the ramp-up period lasts four months before reaching the full dose.